Adriamycin
Malignant Epithelial Tumor Of Ovary
Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
National Cheng-Kung University Hospital
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03480750CT.gov Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Epithelial Tumor Of Ovary
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | National Cheng-Kung University Hospital | P1/2 | CCC · 52 |
| Carboplatin | Wake Forest University Health Sciences | P2 | BB |
| Niraparib | CanariaBio Inc. | P2 | CCC |
| Trientine | National Cheng-Kung University Hospital | P1/2 | CCC |
| Avelumab | University of Texas Southwestern Medical Center | P2 | CCC |
| Oregovamab | CanariaBio Inc. | P2 | CC |
| Dordaviprone | Ira Winer | P2 | CC |
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Adriamycin in Malignant Epithelial Tumor Of Ovary. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adriamycin-malignant-epithelial-tumor-of-ovary
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →